EVEN YEHUDA, Israel, March 3, 2014 /PRNewswire/ — Bluesphere Corp. (BLSP) (the “Company” or “Bluesphere”), an energy company that develops, manages and owns waste-to-energy projects, announced today its wholly-owned subsidiary has signed a Joint Venture Agreement with Alfa Eco Corporation. New York-based Alfa Eco is a leading private business group that consists of direct investment funds owning and managing assets in a range of industries, including energy in the United States and abroad. Alfa Eco has strategic partnerships in Bulgaria, Brazil, China, Kazakhstan, Mongolia, Russia, Sierra Leone, Switzerland, Ukraine and other countries.

Per the terms of the Joint Venture Agreement, Bluesphere and Alfa Eco will form a joint venture corporation jointly owned by the companies on a 50%/50% basis. Through the joint venture, the companies will develop turn-key and build-own-operate (“BOO”) waste-to-energy projects. Alfa Eco will provide turnkey and BOO projects with all required components in place (e.g., power purchase agreements, feedstock, etc.), while Bluesphere will arrange full financing and be the project integrator on the waste-to-energy projects.

“We are very pleased to form this joint venture corporation with Alfa Eco, a company which has resources and relationships that can support the development of numerous joint waste-to-energy projects in partnership with Bluesphere,” stated Bluesphere CEO Shlomi Palas. “Our ability to establish joint ventures, project financing, and long-term revenue contracts with energy industry leaders such as Alfa Eco is a testament to Bluesphere’s capabilities and reputation in the waste-to-energy market.”

Bluesphere generates electricity from biogas derived from organic waste, which is mostly food waste, and sells this electricity to leading electric companies through long-term power purchase agreements. Waste-to-energy is one of the fastest growing segments in the renewable energy markets. According to SBI Energy, the thermal and biological segments reached $6 billion in 2012 and will reach $29 billion by 2022.

For further information please contact Mark Radom at 972 52 798 0831 or info@bluespherecorporate.com.

About Alfa Eco Corporation
Alfa Eco was originally founded in 1989 as cooperative between Alfa Photo and ADP (Mikhail Fridman & Anatoly Potik). Since then, Mr. Potik re-developed the Alfa Eco Corporation. Alfa Eco is a leading private business group that consists of direct investment funds owning and managing assets in life science/healthcare, energy, metals & mining, construction development, agriculture, and education sectors in the United States and abroad. Alfa Eco has strategic partnerships in Bulgaria, Brazil, China, Kazakhstan, Mongolia, Russia, Sierra Leone, Switzerland, Ukraine and other countries. The strategy of Alfa Eco is targeted at the acquisition of assets in industries with a significant growth and consolidation potential. The company is also dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions.

About Bluesphere Corporation
Bluesphere Corporation is a company in the cleantech sector as a waste-to-energy project Integrator. Bluesphere develops waste-to-energy and other renewable energy projects. The Company aspires to become a key player in the global waste-to-energy and renewable energy markets. For further information please visit the Company’s website www.bluespherecorporate.com.

ROCKVILLE, Md.–(BUSINESS WIRE)–

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the appointment of Mark P. Carthy to the company’s Board of Directors.

“We are very pleased to have Mark join Rexahn’s Board of Directors,” said Peter D. Suzdak, Ph.D., Rexahn’s Chief Executive Officer. “Mark’s extensive business and financing experience in the life sciences will be particularly important as we continue the development of our three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902) for the treatment of multiple types of cancer.”

Dr. Chang Ahn, Ph.D., Chairman of the Board of Directors of Rexahn added, “Mark’s significant industry experience and leadership, which spans over more than 30 years in both pharmaceutical and smaller biotechnology companies, will be a tremendous asset to the Company. We welcome Mark to the Board of Directors and I am confident he will assist Rexahn in continuing to build value for our stockholders while we develop potentially life-saving treatments for patients.”

Mr. Carthy is the Managing Partner of Orion Equity Partners, LLC, a healthcare venture capital management and advisory firm co-founded by Mr. Carthy in 2008. Prior to founding Orion, Mr. Carthy was a Venture Partner and General Partner at Oxford Bioscience Partners, an early stage venture capital firm that provides equity financing and management assistance to companies within the life sciences, technology, energy and healthcare sectors. From 1998 until 2000, Mr. Carthy served as the Biotechnology Portfolio Manager at Morningside Ventures where he focused on early stage private equity investments. Previously, he was Chief Business Officer of Cubist Pharmaceuticals and Senior Director of Business Development at Vertex Pharmaceuticals. Mr. Carthy served as a member of the board of the New England Venture Capital Association from 2006 until 2013 and was listed on the Forbes Midas List in 2009 as one of the leading venture capitalists. He received a Bachelor of Chemical Engineering from the University College Dublin, Ireland, a Master of Science in Chemical Engineering from the University of Missouri and a Master of Business Administration from the Harvard Graduate School of Business Administration.

About Rexahn Pharmaceuticals, Inc.

Rexahn Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to developing best-in-class therapeutics for the treatment of cancer. Rexahn currently has three clinical stage oncology candidates, Archexin®, RX-3117, and Supinoxin™ (RX-5902), and a robust pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. For more information, please visit www.rexahn.com.

VIENNA, Va.–(BUSINESS WIRE)–

Over the past three months, patient screening by participating hospitals and patient enrollment have steadily increased. In fact, we are even now seeing patient enrollment at centers that had not enrolled any patients under the prior Clinical Research Organization (CRO), inVentiv Health. CEL-SCI expects to see a further increase in the number of patients enrolled in the study at an accelerating pace as (i) the current centers finalize all logistical issues and (ii) an additional 50-60 centers are added throughout the world. Full enrollment of the planned 880 patients is expected by the end of 2015.

Per the study’s protocol design, four out of every seven patients enrolled are randomized to treatment with Multikine followed by the current standard of care (SOC) treatment, which is surgery plus radiotherapy or surgery plus concurrent radiochemotherapy. The remaining three patients receive SOC only – the control-treatment comparator group. In accordance with the protocol design, of the approximate 146 patients enrolled, an estimated 84 have already been dosed with Multikine.

The study’s Independent Data Monitoring Committee (IDMC), a committee of prominent physicians and scientists from around the world, already has completed two interim reviews of the unblinded trial data. Following each review, the IDMC concluded that the patient data raised no safety concerns and recommended that the Phase III study continue unmodified.

“We are very pleased with the acceleration of our study and based on what we are told by our current CROs Ergomed and Aptiv Solutions, we believe that both patient accrual and the study will continue to advance at a faster pace in the coming months,” stated CEL-SCI Chief Executive Officer Geert Kersten.

Most of the patient enrollment is under the control of Ergomed who has signed three co-development agreements for Multikine with CEL-SCI. The agreement concerning head and neck cancer calls for an investment by Ergomed of up to $10 million into the ongoing Phase III clinical trial. Ergomed will be repaid from future sales of Multikine, following regulatory approval.

Pompano Beach, Feb. 27, 2014 (GLOBE NEWSWIRE) — DS Healthcare Group, Inc. (DSKX), a leading developer of personal care products, today announced it is in the process of opening its first DS Laboratories retail store scheduled to open in the third quarter of 2014. The store, to be located in the metro Miami area, will showcase DS Healthcare’s line of products including its industry-leading Spectral line of hair loss treatments and Revita hair stimulating shampoo and conditioner. The move is part of the Company’s broader strategy as it continues to build the premier global brand in clinically proven personal care products.

DS Laboratories, the Company’s flagship brand is now sold in over 15 countries, helping address a global and underserved problem of hair loss. The Company’s first retail store in Miami will continue to increase brand awareness while adding to revenues and gross margins.

“Customers worldwide who have tried our products have a passion for them because they work. We believe our products, in particular our hair loss formulations, are the most effective on the market. With the opening of our first DS Laboratories retail store, we create an opportunity to increase our direct connection with consumers, leverage our marketing and advertising campaigns, and drive greater demand to the thousands of stores and salons that already carry our products,” stated DS Healthcare President and CEO Daniel Khesin.

About DS Healthcare Group

DS Healthcare Group Inc. leads in the development of biotechnology for topical therapies. It markets through online and specialty retailers, distributors, cosmetics wholesalers, and salons. Its research has led to a highly innovative portfolio of personal care products and additional innovations in pharmaceutical projects. For more information on DS Health Group’s flagship brand, visit www.dslaboratories.com

Forward-looking statements

Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies, and are generally preceded by words such as “future,” “plan” or “planned,” “expects,” or “projected.” These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company’s control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing and marketing products, intense competition, and additional risks factors as discussed in reports filed by the company with the Securities and Exchange Commission, which are available at http://www.sec.gov.

WILMINGTON, Mass., Feb. 27, 2014 /PRNewswire/ — Implant Sciences Corporation (IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, announced today that its QS-B220 desktop explosives trace detection system has successfully completed and passed testing requirements of the Qualification Testing and Evaluation (QT&E) portion of the Transportation Security Administration’s (TSA) Explosive Trace Detection (ETD) qualification test at the Transportation Systems Integration Facility (TSIF).

TSA’s state-of-the-art TSIF, located at Ronald Reagan Washington National Airport, is where new screening technologies are tested before they are deployed to airports around the country. The facility provides an operational airport environment where TSA evaluates the technology by its concepts of operation, measures of performance, and measures of effectiveness.

In July 2013, the QS-B220 successfully completed the first step of QT&E, called Independent Testing and Evaluation (IT&E). QS-B220 has since passed the second step of QT&E at the TSIF, thereby fulfilling another important step towards qualifying the QS-B220 by the Transportation Security Administration and for use in major airports all across the US.

“Evaluation of our QS-B220 was a very important achievement that demonstrates the benefits of our ETD technology in action. The QS-B220 provides superior detection capabilities, a non-radioactive source, and operational and cost efficiencies that can deliver benefits at airport security checkpoints each year. The combination of enhanced performance and operational capabilities of the QS-B220 truly define the new standard of trace detection,” stated Glenn D. Bolduc, Implant Sciences’ President and CEO.

“Successfully completing QT&E brings us another step closer to completing TSA’s Qualified Product List process, and we are confident that the QS-B220 will meet the remaining stringent testing requirements,” added Dr. Darryl Jones, Vice President of Sales and Marketing at Implant Sciences.